Author name: li6230933@gmail.com

This article shares practical, field-based experience on designing robust analytical methods for complex intermediates, focusing on impurity identification, method robustness, and regulatory expectations.

The Rise of High-Potency Intermediates highlights a fundamental shift in pharmaceutical manufacturing, where potency-related risks emerge early at the intermediate stage. As oncology and targeted therapies expand, manufacturers must integrate exposure control, impurity strategy, and scalable process design to ensure compliance, safety, and long-term supply reliability.

This article shares real-world insights from two decades of pharmaceutical process development, focusing on how synthesis route design for complex intermediates directly impacts cost, scalability, impurity control, and regulatory compliance.

Explore key pharmaceutical intermediates for cardiovascular drugs, manufacturing requirements, and global market demand supported by regulatory and industry data.

Crystallization and solid-form control are critical to intermediate quality, scalability, and downstream API performance. This article explores common solid-state challenges, scale-up risks, and why early crystallization expertise at the intermediate stage reduces development and regulatory uncertainty.

Orforglipron is Eli Lilly’s oral GLP-1 receptor agonist for weight management, currently under FDA review. This article examines its clinical background, weight-maintenance data, and implications for pharmaceutical development and intermediates.

Learn why batch-to-batch consistency is critical for pharmaceutical intermediates, impacting impurity control, scale-up success, and regulatory compliance.

This article examines the core technical challenges faced during oncology intermediate manufacturing, including reaction selectivity control, impurity structural fixation, and scale-up consistency risks.

This article provides an in-depth analysis of the most common scale-up challenges encountered during the production of pharmaceutical intermediates.

Learn proven, production-level strategies for impurity control in pharmaceutical intermediates. This guide explains impurity sources, control methods, and batch consistency practices.